Inventiva S.A. (IVA) Q2 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you and welcome everybody to this half-year webcast. As usual, some disclaimer, we'll be making forward-looking statements, so please have a look at our regulatory filings that are available on our website. In terms of speakers, I would say we have the classical Infinitiva team, myself and Pierre, the co-founders of the company. We have Michael, our CMO, and Jean, our CFO. But today is a special day for Inventiva, given the very recent partnership we signed with CenoBioPharm online in February. We are very pleased to have with us Philip Duong, head of the investment, who will give us an overview of CenoBioPharm activities. In terms of agenda, I'll give an highlight of the activity over the past six months, and then I will share the floor with Philippe, with Pierre, with Michael, to provide a pipeline update. We will move to the financial section with Jean, near-term catalyst, and then we will open the floor for Q&A. So, moving now to the highlight section, we start first with Lani, our phase three drug in non-alcoholic steroid hepatitis. A lot of key important milestones have been reached in the past six months. In terms of native three, we have expanded in 24 countries, and we have now activated close to 300 sites. And in the presentation, we give you a bit more details on the improvement in terms of cytotoxin. Very pleased, as I mentioned in my introduction, of the very recent collaboration we signed with SinoBioPharm and the expansion of Lani in Greater China, a country that we see is really promising from a commercial point of view, given the prevalence of NASH among the Chinese population. Some of the figures or the key figures of the collaboration are highlighted here, the upfront, the total milestone, the royalties, and we'll get a bit more in detail in ...